Abstract:Background: Cancer treatment is based on tumor staging. Curative intent is only applied to localized tumors. Recent studies show that oligometastatic patients who have limited number of metastases may benefit from metastasis-directed local treatments to achieve long-term survival. However, mechanisms underlying oligometastatic to polymetastatic progression remains elusive. Methods: The effects of miR-200c and Sec23a on tumor metastasis were verified both in vitro and in vivo. The secretome changes were detected by mass spectrometry. Findings: We established a pair of homologous lung-metastasis derived oligometastatic and polymetastatic cell lines from human melanoma cancer cell line M14. Using the two cell lines, we have identified Sec23a, a gene target of miR-200c, suppresses miR-200c augmented oligometastatic to polymetastatic progression via its secretome. Firstly, miR-200c over-expression and Sec23a interference accelerated oligometastatic to polymetatic progression. Secondly, Sec23a functions downstream of miR-200c. Thirdly, mass spectrometric analysis of the secretory protein profile suggests that Sec23a-dependent secretome may impact metastatic colonization by modifying tumor microenvironment. Fourthly, the survival analysis using The Cancer Genome Atlas database shows Sec23a as a favorable prognostic marker for skin cutaneous melanoma, supporting the clinical relevance of our findings. Interpretation: The finding that Sec23a is a suppressor of oligometastatic to polymetastatic progression has clinical implications. First, it provides a new theoretical framework for the development of treatments that prevent oligometastasis to polymetastasis. Second, Sec23a may be used as a favorable prognostic marker for the selection of patients with stable oligometastatic disease for oligometastasis-based local therapies of curative intent. FUND: National Natural Science Foundations of China.

Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis

Selective Requirement For Mediator Med23 In Ras-Active Lung Cancer

MED23 depletion induces premature senescence in NSCLC cells by interacting with BCLAF1 and then suppressing NUPR1 expression

Mediator MED23 Regulates Inflammatory Responses and Liver Fibrosis

A Mediator Lost in the War on Cancer

The Mediator Subunit MED23 Couples H2B Mono‐ubiquitination to Transcriptional Control and Cell Fate Determination

Methyltransferase-like 3 promotes the progression of lung cancer via activating PI3K/AKT/mTOR pathway

The molecular mechanism of METTL3 promoting the malignant progression of lung cancer

Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy

The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis

Mediator MED23 Plays Opposing Roles in Directing Smooth Muscle Cell and Adipocyte Differentiation.

Dynamin 3 Inhibits the Proliferation of Non-small-Cell Lung Cancer Cells by Suppressing c-MET–GBR2–STAT3 Complex Formation

The Role of TGFBR3 in the Development of Lung Cancer

Mediator Med23 Regulates Basal Transcription In Vivo Via An Interaction With P-Tefb

The Mediator Med23 controls a transcriptional switch for muscle stem cell proliferation and differentiation in muscle regeneration

TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR

Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1

LRRC45 promotes lung cancer proliferation and progression by enhancing c-MYC, slug, MMP2, and MMP9 expression

Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression

M6a Methyltransferase METTL3 Promotes Non-Small-cell Lung Carcinoma Progression by Inhibiting the RIG-I-MAVS Innate Immune Pathway

Med23 Supports Angiogenesis and Maintains Vascular Integrity Through Negative Regulation of Angiopoietin2 Expression